Related Experiment Video

Updated: Aug 31, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Signal transduction and myeloma: new targets, new hope

Sagar Lonial1, Edmund K Waller, Jonathan W Simons

  • 1Winship Cancer Institute; Emory University School of Medicine; Atlanta, Georgia USA. sloni01@emory.edu

Cancer Biology & Therapy
|September 26, 2003
PubMed

Insights

Multiple Myeloma, a plasma cell cancer, has limited survival rates. Novel molecular therapies offer new hope, moving beyond palliative care for better patient outcomes.

Area of Science:

  • Hematologic Malignancies
  • Cancer Biology
  • Molecular Therapeutics

Background:

  • Multiple Myeloma is a plasma cell malignancy with historically limited long-term survival.
  • Current therapies are often palliative, highlighting the need for advanced treatment strategies.

Purpose of the Study:

  • To review current and emerging therapies for Multiple Myeloma.
  • To explore the molecular basis of novel treatment options.
  • To assess future targeted approaches and early-phase drug development.

Main Methods:

  • Literature review of existing and novel Multiple Myeloma treatments.
  • Analysis of molecular mechanisms underlying disease development and therapeutic response.
  • Evaluation of early-phase clinical trial data for new agents.

Main Results:

  • Traditional therapies like corticosteroids and alkylating agents have limited efficacy.
  • Emerging treatments including proteasome inhibitors and immunomodulatory drugs show promise.
  • Targeted therapies and agents in early development represent future directions.

Conclusions:

  • Understanding myeloma's molecular biology is crucial for developing effective treatments.
  • Novel therapies are expanding treatment options beyond palliative care.
  • Continued research into targeted approaches and early-phase agents is vital for improving survival.

More Related Videos

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...